head of Lilly Oncology. The agreement isn't Lilly's first attempt to make a mark in the PI3K inhibitor class, having previously been working on LOXO-783, a drug it acquired as part of its $8 ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...

Jake Van Naarden, executive vice president and president, Lilly Oncology, will take part in a fireside chat at 1:50 p.m., Eastern time. A live audio webcast will be available on the "Webcasts ...

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...

Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly to discover, develop and commercialise ...

Joining us from the Company is Jake Van Naarden, who is President of Lilly Oncology. So, thank you so much, Jake, for being with us. Yes. So, I think, in the late phase portfolio on the R&D side ...

Eli Lilly is investing an additional $27 billion to boost domestic drug production as President Donald Trump reaffirms his commitment to imposing tariffs to restore manufacturing in the U.S. The ...

Advertisement Eli Lilly chairman and Chief Executive Officer ... to produce medicines that support cardio-metabolic health, oncology, immunology and neuroscience treatments.